drug
meloxicam
Marketedupdated 3mo agoby Nanjing Delova Biotech Co Ltd
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugcyclobenzaprine hydrochloride2 co-mentions · 1 sources
- drugMR-107A022 co-mentions · 2 sources
- drugmeloxicam SR2 co-mentions · 2 sources
- drugcyclobenzaprine hydrochloride ER2 co-mentions · 1 sources
- tagRecall2 co-mentions · 2 sources
- drugCyclobenzaprine Hydrochloride Teva2 co-mentions · 1 sources
- companyUnichem Pharmaceuticals (USA) Inc1 co-mentions · 1 sources
- companyUnichem Laboratories Ltd1 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 14 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying meloxicam
- phase3Initiating Early Control of Migraine Pain and Associated Symptoms
- phase3Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
- phase3Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery
- phase1Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects
- phase3Efficacy and Safety of Injectable Association of Dexamethasone, Dipyrone and Hydrocobalamin in Lumbar Sciatic Pain
- phase1Meloxicam 15 mg Tablets Under Fasting Conditions
- phase1Meloxicam 15 mg Tablets Under Non-Fasting Conditions
- phase1Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 26, 2030
~3.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Jul 31, 2041formulationUS 12263176
- Jul 19, 2040compositionUS 12059423
- Mar 8, 2039method-of-use (U-3038)US 10881663
- Mar 8, 2039method-of-use (U-3318)US 11458145
- Mar 31, 2035formulationUS 9649318
- Mar 31, 2035formulationUS 9649318
- Mar 31, 2035method-of-use (U-2165)US 9808468
- Mar 31, 2035method-of-use (U-2160)US 9808468
- Mar 31, 2033formulationUS 9526734
- Mar 31, 2033formulationUS 9526734
- Aug 31, 2030formulationUS 85458794.0y
- Aug 31, 2030formulationUS 85458794.0y
- May 26, 2030method-of-use (U-2750)US 107097133.8y
- May 26, 2030formulationUS 112534783.8y
- May 26, 2030formulationUS 99747463.8y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that